For US Healthcare Professionals

You are now leaving the site

Are you sure you want to leave?

Support for your Patients

Amgen By Your Side is a support program for patients prescribed TEPEZZA. The Amgen By Your Side team partners with your patient to provide non-medical personalized support as they start and continue treatment as you prescribe.

After your patient has enrolled, we will pair them with a dedicated Patient Access Liaison (PAL). Our mission is to connect, coordinate, and champion your patient at the most important steps along the way:

connect
CONNECT: Your patient will be connected to one person dedicated to partnering with them throughout their treatment experience
COORDINATE: Your patient will receive educational support on insurance, financial assistance options, important appointment-related information, and more
CHAMPION: Your patient’s dedicated partner will strive to empower them to be confident self-advocates committed to maintaining their treatment goals
patient-border patient-border-mobile
What Amgen By Your Side can do to support your patients:
  • Educate patients on the results of their benefits investigation and review their insurance coverage
  • Help patients understand potential out-of-pocket costs and financial assistance options
  • Educate you and your staff about insurance processes, including specific payor requirements and examples
  • Provide education to you and your staff about product coding and billing
  • Provide site of care options for you and your patients, if needed
  • Share additional resources that may be helpful as your patient gets started
Carol

"I help patients understand what is needed to access treatment and empower them to be their own advocate."

 

—Carol E., PAL

Explore everything Amgen By Your Side offers to your appropriate patients 

Amgen believes patients should pay the lowest amount possible

 

Paying for treatment shouldn’t get in the way of health. That’s why the Amgen By Your Side team is diligent in exploring all options to help your patients* 
co-pay
Patients with commercial insurance may be eligible for a $0 co-pay for the cost of the medication and the infusion administration through our Amgen Commercial Co-Pay Program.*
*Subject to terms and conditions.

Terms and Conditions:

Offer cannot be combined with any other rebate or coupon, free trial, or similar offer for the specified prescription. Not valid for prescriptions reimbursed in whole or in part by any government-funded program including but not limited to Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE, or any state, patient foundation, or other pharmaceutical program. Offer good only in the United States at participating specialty pharmacies or sites of care. Offer not valid where otherwise prohibited by law, for example by applicable state law prohibiting co-pay cards. Amgen reserves the right to rescind, revoke, or amend offer without notice. The selling, purchasing, trading, or counterfeiting of any co-pay card or benefits is prohibited by law. This co-pay program is not insurance and is not intended to substitute for insurance. Age for eligibility is dependent on product indication.
  • Does your patient have commercial insurance?
    They may qualify for $0 co-pay for both the cost of the medication and the intravenous infusion
  • Does your patient have government insurance, like Medicare?
         Independent foundation support might be an option†
  • Who can help educate your patients on the insurance approval process?
    Once your treatment plan is set in place, the Patient Access Liaison can help by talking with your patient about the insurance approval process and potential out-of-pocket treatment costs
  • Is your patient uninsured?
    Contact the Amgen By Your Side team at 1-833-5-TEPEZZA (1-833-583-7399) to discuss support options

†Please note that independent foundations establish, administer, and implement the funds, which are separate and apart from Amgen. While we cannot guarantee access or reimbursement for our medicines, we can educate you and your staff about gaining access to the medicine and various patient financial support programs.

*The Amgen Commercial Co-pay Program may be available to patients who meet the following minimum criteria:
  • Patient’s prescription cannot be paid in part or in full by any government-funded program including but not limited to: Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, Department of Defense (DOD), TRICARE, or any state, patient foundation, or other pharmaceutical program 
  • Patient is prescribed a covered Amgen rare disease medication for an indication approved by the Food and Drug Administration; the indication for each product is shown in its prescribing information
  • Patient is a resident of the United States
  • Patient must be commercially insured and have financial responsibility for a portion of the drug and/or infusion cost if applicable
The assistance offered under this co-pay program is subject to additional terms and conditions, including but not limited to the following:
 
Terms and Conditions: Offer cannot be combined with any other rebate or coupon, free trial, or similar offer for the specified prescription. Not valid for prescriptions reimbursed in whole or in part by any government-funded program including but not limited to: Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE, or any state, patient foundation, or other pharmaceutical program. Offer good only in the United States at participating specialty pharmacies or sites of care. Offer not valid where otherwise prohibited by law, for example by applicable state law prohibiting co-pay cards. Amgen reserves the right to rescind, revoke, or amend offer without notice. The selling, purchasing, trading, or counterfeiting of any co-pay card or benefits is prohibited by law. This co-pay program is not insurance and is not intended to substitute for insurance. Age for eligibility is dependent on product indication.
 
Participating Pharmacies or Healthcare Providers: By using this co-pay program, you acknowledge and confirm that the prescription will not be reimbursed in whole or in part by any government-funded program (such as, without limitation, Medicare, Medicaid, VA, DOD, TRICARE) and the patient and prescription meet the eligibility criteria set forth in the terms and conditions. You are responsible for reporting the receipt of the co-pay program benefits as required by an insurer, payor, or applicable law or regulation.
 
Patients: By enrolling in this co-pay program, you acknowledge and confirm that you and the prescription meet the eligibility requirements set forth in the terms and conditions, including that the prescription will not be reimbursed in whole or in part by any government-funded program (such as, without limitation, Medicare, Medicaid, VA, DOD, TRICARE). You may not seek any claims to government payors or other payors or insurers for this prescription. You may not seek reimbursement from any health savings, flexible savings, or other healthcare reimbursement account for any amounts received from the co-pay program. You are responsible for reporting the receipt of the co-pay program benefits as required by an insurer, payor, or applicable law or regulation.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD. If IBD exacerbation is suspected, discontinue use of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, ear discomfort, weight decreased, nail disorders, and menstrual disorders.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Please see Full Prescribing Information for more information.